flow cytometry, increased proliferating cell nuclear antigen (PCNA) index, elevated level of serine proteases like urokinase and plasminogen, and a high microvessel count (Rosvold, 1996) .
With the advance in molecular biology some genetic changes have been suggested to be useful prognostic markers. Mutations in K-ra s , overexpression of c-er bB-2 protein (Kern et al, 1990 (Kern et al, , 1994 Tateishi et al, 1991) , mutation of p53 (Mitsudomi et al, 1993) and lack of Rb1 (Xu et al, 1994) or bcl-2 protein expression (Pezzella et al, 1993; Fontanini et al, 1995) have all been reported as adverse prognostic factors.
Recently, in addition to mitogens and tumour suppressor genes, some of the essential components of cell cycle machinery itself have been found to show oncogenic potential (Motokura and Arnold, 1993; Lovec et al, 1994) . Among them, cyclin D1 appears to be the most strongly implicated in tumorigenesis. Cyclin D1 has a regulatory role in the G1 to S transition of the cell division cycle. There have been genetic evidences of tumour-specific rearrangements and amplifications of the cyclin D1 gene in the experimental-induced malignant phenotype (Bartkova et al, 1994; Lovec et al, 1994; Lukas et al, 1994; Wang et al, 1994) .
The role of cyclin D1 protein in human cancers has recently been able to be performed in a la rge scale using a monoclonal antibody specific for this oncoprotein with an optimizing protocol for immunohistochemical detection of cyclin D1 on archival tissue sections (Gillett et al, 1994; Bartkova et al, 1995) . Some of the human primary cancers have been found to have amplification or overexpression of the relevant gene locus of cyclin D1 including breast (Gillett et al, 1994; McIntosh et al, 1995; Simpson et al, 1997) , oesophagus (Jiang et al, 1992; Adelaide et al, 1995) , liver Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer (Zhang et al, 1993; Nishida et al, 1994) , head and neck (Callender et al, 1994 , Michalides et al, 1995 and urinary bladder cancers (Proctor et al, 1991; Shin et al, 1997) .
A few studies have reported that overexpression of cyclin D1 is implicated in the tumorigenesis of NSCLCs (Betticher et al, 1996; Kwa et al, 1996; Mate et al, 1996; Caputi et al, 1997) . However, there has been controvery and limited available data for the significance of cyclin D1 overexpression on the prognosis of NSCLC patients. In the present study, we have investigated whether immunohistochemically detected cyclin D1 overexpression is associated with the survival of patients with early-stage resectable NSCLCs.
MATERIALS AND METHODS

Tumour samples
The tumour specimens were obtained from lobectomies or pneumonectomies performed at the Hanyang University Hospital placed in Seoul, Korea between 1985 and 1994. Consecutive 69 NSCLC patients with resectability were selected after pathological examination of the formalin-fixed and paraffin-embedded tumour specimens (stage IÐIIIa) (stage I (T1Ð2 N0 M0), stage II (T1Ð2 N1  M0), stage IIIa (T1Ð3 N2 M0, T3 N0 M0, T3 N1 M0) ) (Mountain, 1986) . The patients had been followed up through a period ranging from 0.5 to 108 months after resection of the primary tumour.
Immunohistochemical study
Immunohistochemical staining was performed by the method previously described (Shin et al, 1997) . Briefly, representative tissue sections from 69 cases were deparaffinized and rehydrated. After boiling the slides in a microwave oven (containing 0.01 M sodium citrate buffer pH 6.0; 800 W), endogenous peroxidase was blocked with 3% hydrogen peroxideÐmethanol. After washing with cold 0.5 M Tris-buffered saline (TBS), non-specific binding was inhibited by incubation with normal goat serum (Dako, Carpenteria, CA, USA) for 20 min. Monoclonal mouse antihuman cyclin D1 (P2D11F11, 1:200 in dilution, Novocastra, Newcastle, UK) and PCNA antibodies (PC10, 1:100 in dilution; Dako) were applied and incubated for 30 min. After washing with TBS three times, the sections were incubated with biotinylated antimouse IgG (Dako) for 30 min. After washing, peroxidaseÐantiperoxidase conjugate (Dako) was applied. They were then stained with diaminobenzidine tetrahydrochloride (Dako) and counterstained with MeyerÕs haematoxylin. Positive control was identified on the sections from formalin-fixed and paraffin-embedded WI-38 cells (ATCC, Rockville, MD, USA) for cyclin D1. Negative control was accompanied by applying phosphate-buffered saline instead of cyclin D1 and PCNA antibodies.
Analysis
Immunohistochemical reactivity of cyclin D1 was interpreted as positive when there was distinct nuclear staining with a brownish tincture in more than 5% of the tumour cell population (Michalides et al, 1995; Shin et al, 1997 ) ( Figure 1A ). For PCNA, distinct nuclear staining with a brownish tincture was considered as positive and the index of PCNA was calculated in percentage of positive cells among approximately 1000 counted tumour cells ( Figure 1B) .
The correlation of cyclin D1 immunoreactivity with clinical factors such as age, sex, histopathological type, stage of the tumour, extent of the primary tumour, metastatic status of the lymph node and PCNA index was analysed through the MannÐWhitney U-test or analysis of variance (ANOVA) according to the characteristics of the data. Overall survival in relation to cyclin D1 immunoreactivity was analysed with the KaplanÐMeier method, and their difference with the log-rank test. Multivariate analysis for survival was assessed using a forward step-wise Cox regression model. The variables included tumour (T) and nodal status of TMN system, stage of the tumour and cyclin D1 positivity. The statistical analysis was performed using the SPSS 7.5 software package (SPSS Inc., Chicago, IL, USA). P < 0.05 was considered statistically significant.
RESULTS
Clinical features
Among 69 patients, 53 were men and 16 were women. The age difference ranged from 40 to 73 years (mean 57.2 years). The clinical follow-up period was between 0.5 months and 108 months. Twenty cases were in stage I, 13 in stage II and 36 in stage IIIa. There were 41 squamous cell carcinomas, 21 adenocarcinomas and seven large-cell undifferentiated carcinomas. Two giant cell carcinomas were included in the latter group. Five were T1, 43 T2 and 21 T3 in accordance with the extent of the primary tumour. Twenty-seven patients were free of tumour metastasis in both dissected and biopsied lymph nodes. Twenty-one patients showed ipsilateral bronchopulmonary or hilar nodal metastasis and the other 21 patients had metastasis in the ipsilateral subcarinal mediastinal lymph node.
Immunohistochemical analysis of cyclin D1
Twenty-four tumours (34.8%) revealed positive immunoreactivity for cyclin D1. The relationship between cyclin D1 immunoreactivity and clinicopathological features are summarized in Table 1 .
Cyclin D1 overexpression was higher in female patients (50%) than in male patients (30.9%), but there was no significant difference between the two groups (P = 0.394). The cyclin D1 immunopositive group was slightly younger than the negative group with no significant difference (P = 0.347). Among the three histopathological subgroups, adenocarcinoma showed the most frequent positivity (47.6%) followed by squamous cell carcinoma and large-cell carcinoma (31.7% and 14.3% respectively). However, no significant difference was present among the three groups (P = 0.784). Although all five T1 tumours showed no immunoreactivity, T2 and T3 tumours revealed 39.5 and 33.3% of positive immunoreactivity respectively. There was no significant difference (P = 0.637). Cyclin D1 immunoreactivity was well correlated with lymph node metastasis and the stage of the tumour. Twenty-one of 42 NSCLCs with lymph node metastasis (50%) showed positive immunoreactivity for cyclin D1. However, only three of 27 nodal metastasis-free cases (11%) disclosed cyclin D1-positive immunoreactivity. This difference was highly significant (P = 0.002). According to the stage of the tumour, stage I showed a lower cyclin D1-positive immunoreactivity than stages II and IIIa (10%, 53.8%, and 41.7% respectively). There were significant differences (P = 0.006 for stage I vs II, IIIa; P = 0.048 for the three groups).
PCNA index
All tumours showed a variable degree of positive immunoreactivity for the PCNA protein in their nuclei. However, there was no significant difference in different groups according to sex, histopathological subtype, extent of the primary tumour (T status), nodal status, or stage of the tumour (ANOVA). The PCNA index was slightly higher in cyclin D1-positive groups in comparison with cyclin D1-negative groups (53.2% vs 47.3% respectively). However, no significant difference was present (ANOVA, P = 0.117).
Survival of the patients
The overall survival ranged from 0.5 to 108 months. During the follow-up period a total of 48 patients (30.4%) died and 21 were censored. The survival of the total 69 patients according to various factors are presented in Table 2 . The overall survival in the present study was significantly correlated with the extent of the primary tumour, nodal status and stage of the tumour (log-rank; P = 0.0133, P = 0.0002 and P < 0.00001 respectively). However, the histological type of the NSCLC and sex of the patients were not correlated with patient survival (P = 0.1887 and 0.6129 respectively). Sixteen of 45 cyclin D1-negative cases (35.6%) were censored. The mean survival of the cyclin D1-negative groups was significantly longer than that of the cyclin D1-positive groups (50.1 ± 6.4 months vs 24.0 ± 3.9 months, P = 0.029). An analysis of the overall survival in stages IÐII and stages IÐIIIa revealed that cyclin D1-positive immunoreactivity was strongly associated with a poorer overall survival (P = 0.0066 and P = 0.0299 respectively; Figure 2 ). Multivariate analysis showed that the stage of the tumour was the strongest prognostic factor (P = 0.0082). However, cyclin D1-positive immunoreactivity was not significant (P = 0.3878) ( Table 3) .
DISCUSSION
Abnormal expression of cell cycle-regulatory proteins commonly occur in various human cancers (Motokura et al, 1993; Bartkova et al, 1994; Lovec et al, 1994; Lukas et al, 1994; Wang et al, 1994) . One of the most frequent derangements is altered expression of cyclin D1. Cyclin D1 is encoded by CCND1 (PRAD1 and BCL-1) located in the chromosome 11q13 region which also harbours EMSI, HSTF1 and INT2 genes. Cyclin D1 protein stimulates cyclin-dependent kinase (cdk)-mediated phosphorylation of the retinoblastoma susceptibility gene (Rb) product, which inactivates its growth-suppressive role to the transcription factor E2F. The cyclinÐcdk complexes lead to transition of cell division from G1 to S phase, thus contributing to tumorigenesis in many organs by continuing cell cycle progression when they are overexpressed (Kastan and Tooze, 1997) .
In the present study, we detected cyclin D1 overexpression in resected specimens of NSCLC patients using immunohistochemical methods. Twenty-four among 69 patients (34.8%) showed positive immunoreactivity for cyclin D1, which was in the range of previous studies reporting from 18% to 57.1% (Betticher et al, 1996; Kwa et al, 1996; Mate et al, 1996; Caputi et al, 1997) . There have been several reports which showed the correlation of cyclin D1 overexpression or amplification of cyclin D1 gene (CCND1) with pathological prognostic factors and patient outcome in various human cancers. Cyclin D1 gene expression or amplification was associated with not only lymph node metastasis but also with shorter relapse-free survival in breast, head and neck, and urinary bladder cancers (Proctor et al, 1991; Schuuring et al, 1992; Jares et al, 1994; Muller et al, 1994; McIntosh et al, 1995; •kervall et al, 1997; Shin et al, 1997) . With respect to lung cancer, however, there were a few studies reported in the English literature (Betticher et al, 1996; Kwa et al, 1996; Mate et al, 1996; Caputi et al, 1997) . There has been controversy, especially considering the significance of cyclin D1 overexpression on the prognosis of NSCLC patients. Betticher et al (1996) reported that cyclin D1 overexpression has been associated with some pathological parameters such as poorly differentiated histology, less infiltration of lymphocyte and a low incidence of local relapse, which suggested cyclin D1 overexpression as a good prognostic factor. On the other hand, Caputi et al (1997) demonstrated that overexpression of cyclin D1 was significantly related to short-term patient survival. In the present study, cyclin D1 overexpression in resectable NSCLCs was significantly associated with a shorter overall survival, which is compatible with the results of Caputi et al (1997) . Moreover, our data revealed that overexpression of cyclin D1 was also correlated with lymph node metastasis and pathological staging. Therefore, it is suggested that cyclin D1 overexpression detected by immunohistochemical staining may be an indicator of poor prognosis in primary NSCLCs with resectability.
Furthermore, our results revealed that cyclin D1 overexpression was much more strongly correlated with the overall survival among the patients with stages I and II (P = 0.0066 for stages I and II vs P = 0.0299 for stages IÐIIIa). Nine among 33 patients with stages I and II NSCLCs revealed positive immunoreactivity (27.3%), but 15 among 36 (41.7%) stage IIIa patients showed positivity. These findings suggest that overexpression of cyclin D1 can be involved in the tumorigenesis from earlier stages and may play a role in tumour progression to higher stages, which is similar to those of superficial urinary bladder cancers (Shin et al, 1997) .
Our data revealed that there was no significant correlation of cyclin D1 overexpression with histological subtypes of NSCLC. This result may come from the fact that cyclin D1 overexpression is a rather conserved mechanism which is commonly involved in the tumorigenesis of various cell types of NSCLCs.
Mediastinal lymph node involvement in NSCLC is a crucial prognostic factor. Strong correlation between micrometastasis or minimal residual disease of mediastinal lymph nodes detected by immunohistochemical staining and the relapse-free survival or overall survival in stage I NSCLCs further supports the importance of lymph node involvement in the progression of NSCLCs (Izbicki et al, 1996) . In this study, our data demonstrated a strong correlation of cyclin D1 overexpression with lymph node metastasis. This result suggests that metastatic potential in NSCLCs with resectability may become expressed through a way related to deregulation of cyclin D1. Mathematical studies suggest that cells probably need to accumulate at least four to six mutations to become tumorigenic. And each mutation should be required for an expansion of the mutant clone to at least a million cells (20 doublings) in which the next mutation can occur (Shay et al, 1993) . These cell doublings can be achieved through the extended activity of cyclin D1 protein. Overexpression of cyclin D1 should account for their extended activity and clonal expansion of cells that have progression activity such as metastatic potential, thus implicating on the survival of the patients. Taken together with this theoretical background and our results for cyclin D1 protein, correlation of cyclin D1 overexpression with lymph node metastasis may strongly support a possible contribution of cyclin D1 overexpression to the progression and prognosis of NSCLCs.
Overexpression of cyclin D1 is believed to be correlated with increased proliferative activity, as seen in head and neck squamous cell carcinomas measured by flow cytometry (Callender et al, 1994) . But it was difficult to validate correlation with other methods using bromodeoxyuridine labelling or Ki-67 (MIB-1) labelling indices (Zukerberg et al, 1995b) . In the present study, we also measured the proliferative activity by the PCNA index using immunohistochemistry and obtained higher proliferative activity in cyclin D1-positive immunoreactive tumors than in cyclin D1-negative ones. However, no statistically significant difference was present between the two groups.
Cyclin D1 overexpression does not always mean a sine qua non amplification of CCND1. It has been suggested that mechanisms other than gene amplification may play a role in carcinogenesis of lung cancer including increased stability of the protein of clonal rearrangement of CCND1 gene (Zukerberg et al, 1995a) . According to the cytogenetic study, chromosome 11q13 rearrangements were weakly correlated with immunohistochemical overexpression of cyclin D1, although it was a significant prognostic indicator of a poor outcome in head and neck cancers (•kervall et al, 1997) . In NSCLC it also remains to be elucidated whether some putative oncogenes or tumour suppressor genes within the amplicon 11q13 region other than CCND1 may be involved in the tumorigenesis.
In conclusion, our results of cyclin D1 overexpression in relation to various clinicopathological parameters suggest that overexpression of cyclin D1 is involved in tumorigenesis of NSCLC from early stage and could be a molecular marker for a poorer outcome and progression in NSCLCs with resectability. Therefore, cyclin D1 overexpression, especially in patients with stages I and II NSCLCs, may help us to determine its biological behaviour and to choose proper therapeutic modalities following tumour resection.
